Searched for
PMDA
Russia moves to withdraw from plutonium agreement with the United StatesRussia's parliament has approved leaving a key nuclear arms pact with the United States. This agreement, signed in 2000, aimed to reduce la...- US FDA inspects Vishakhapatnam facility of Solara Active PharmaThe US Food and Drug Administration (FDA) completes inspection of Solara Active Pharma Sciences' API manufacturing facility in Visakhapatna...
- Johnson and Johnson Covid jab gets emergency use approvalWith this, Johnson and Johnson became third foreign-made vaccine to get nod after Sputnik V, Moderna; permission is only for imports of the...
- Serum seeks nod for Covovax, J&J for its single-dose vaccineJohnson and Johnson (J&J) and Pune-based Serum Institute of India (SII) have applied to the drug regulator seeking emergency use authorisat...
- Process to receive WHO pre-qualification for Covaxin on: GovtIn response to a question on when the WHO approval for Covaxin is expected, the minister said the data required for approval was submitted ...
- Pfizer, Moderna vaccines may soon be available in IndiaThe Drugs Controller General of India (DCGI) has done away with specific trials of COVID-19 vaccines that have been approved by other inter...
- Sun Pharma bullish on specialty biz, looks to expand the segment to new geographiesSharing information with shareholders, Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company's strategy of develo...
- Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in JapanMumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...
- Parsi woman contests Raj-era personal lawShe said the procedure under the 1938 personal law was exasperatingly cumbersome, involving a system akin to jury decision.
- Lupin gets CDSCO nod for indigestion treatment tabletsAcotiamide is approved by Pharmaceuticals and Medical Devices Agency (PMDA) Japan and is actively marketed in Japan, it added.
- Shilpa Medicare rallies 18% to break out from its 100 to 200-day moving averageThis development comes as a big relief to the company, especially at a time when many of the Indian pharma companies are trapped in regulat...
- Shilpa Medicare zooms on receiving GMP certificate from Japan regulatorShilpa Medicare informed BSE that it has received good manufacturing practice (GMP) compliance certificate for two of its Karnataka-based A...
- Japan's drug regulator PMDA plans India officeJapan wants to lower healthcare costs by encouraging generic drugs. It's looking to double the share of generics in its healthcare system t...
- Japan's drug regulator PMDA set to open office in IndiaThe move is expected to help Indian generic drug manufacturers, which have been seeking to increase their presence in Japan.
- Ind-Swift Labs aims to touch Rs 1,500 crore turnover by 2015Drug firm Ind-Swift Laboratories has set a target of achieving revenues of Rs 1,500 crore by 2015 with overseas markets like Japan.
- Ind-Swift Labs Q3 PAT up 15.52 pc at Rs 28.44 crThe company's profit after tax for the three months ended December 31, 2010 was Rs 24.62 crore, it said in a statement.
- Ind-Swift gets PMDA approval from Japan;stk upInd-Swift has got PMDA approval from Government of Japan for Pioglitazone and Risedronate Sodium to be manufactured at its facilities at De...
- Our consolidated topline is Rs 73 cr: Vishnukant Bhutada, MD, Shilpa MedicareIn an interaction with ET Now, Vishnukant Bhutada, Managing Director, Shilpa Medicare, analyses the company’s earnings figures & product ch...
- Daiichi sets up firm to market Ranbaxy products in JapanRanbaxy’s Japanese parent Daiichi Sankyo has set up a new firm, Daiichi Sankyo Espha Company (DSECL) for marketing generic drugs in Japan.
- Daiichi-Ranbaxy synergy plan delayed, announcement by MarRanbaxy Laboratories and its Japanese parent Daiichi Sankyo's proposal to unveil a three-year plan for exploiting synergies in operations t...
Load More
